Düğeroğlu Harun, Özgenoğlu Murat
MD. Assistant Professor, Department of Internal Medicine, Ordu Üniversitesi Tıp Fakültesi, Ordu, Turkey. Formerly at Van Yüzüncü Yıl Üniversitesi.
MD. Specialist Doctor, Internal Medicine Clinic, Ödemiş Devlet Hastanesi, İzmir, Turkey. Formerly at Van Yüzüncü Yıl Üniversitesi.
Sao Paulo Med J. 2019 Aug 8;137(3):278-283. doi: 10.1590/1516-3180.2018.0481090519.
Gestational trophoblastic diseases (GTDs) are treatable rare tumors with wide distribution. The estimated incidence of GTDs varies dramatically between different regions globally. In early pregnancy, there may be high human chorionic gonadotropin (HCG) concentrations, normal or slightly increased free T4 (fT4) and subnormal thyroid-stimulating hormone (TSH), causing hyperthyroidism ranging from subclinical to severe. Beta-HCG causes thyrotoxicosis through thyroid stimulation in patients with trophoblastic tumors.
To assess thyroid function among patients diagnosed with complete or partial hydatidiform mole, within the GTD spectrum.
Cross-sectional study based on patients' medical records at Van University Hospital, Van, Turkey.
50 patients monitored due to diagnoses of hydatidiform mole were included and were examined regarding thyroid function. Thyroid gland size and volume were measured using thyroid ultrasonography. Beta-HCG, TSH, fT4, free T3 (fT3), total T4 (TT4), total T3 (TT3), anti-thyroid peroxidase (anti-TPO), anti-thyroglobulin (anti-TG) and thyroglobulin levels were measured.
Among these patients, 15 (30%) were diagnosed with complete hydatidiform mole and 35 (70%) with partial hydatidiform mole, according to pathology results. Those with complete hydatidiform mole were older (P = 0.003), with higher number of pregnancies (P = 0.032), lower TSH level (P = 0.011) and higher fT4 and TT4 levels (P = 0.04; P = 0.028), compared with partial hydatidiform mole patients.
In hydatidiform mole patients, thyroid disease severity increases with age, parity, beta-HCG level and mole size. However, prospective multicenter studies on this topic are needed, with larger numbers of patients and closer monitoring.
妊娠滋养细胞疾病(GTDs)是一类可治疗的罕见肿瘤,分布广泛。全球不同地区GTDs的估计发病率差异很大。在妊娠早期,人绒毛膜促性腺激素(HCG)浓度可能升高,游离甲状腺素(fT4)正常或略有升高,促甲状腺激素(TSH)低于正常,导致从亚临床到严重程度不等的甲状腺功能亢进。β-HCG通过刺激滋养细胞肿瘤患者的甲状腺导致甲状腺毒症。
评估GTD范围内诊断为完全性或部分性葡萄胎患者的甲状腺功能。
基于土耳其凡城凡大学医院患者病历的横断面研究。
纳入50例因诊断为葡萄胎而接受监测的患者,并对其甲状腺功能进行检查。使用甲状腺超声测量甲状腺大小和体积。检测β-HCG、TSH、fT4、游离三碘甲状腺原氨酸(fT3)、总甲状腺素(TT4)、总三碘甲状腺原氨酸(TT3)、抗甲状腺过氧化物酶(抗-TPO)、抗甲状腺球蛋白(抗-TG)和甲状腺球蛋白水平。
根据病理结果,这些患者中15例(30%)诊断为完全性葡萄胎,35例(70%)诊断为部分性葡萄胎。与部分性葡萄胎患者相比,完全性葡萄胎患者年龄更大(P = 0.003),妊娠次数更多(P = 0.032),TSH水平更低(P = 0.011),fT4和TT4水平更高(P = 0.04;P = 0.028)。
在葡萄胎患者中,甲状腺疾病的严重程度随年龄、产次、β-HCG水平和葡萄胎大小增加。然而,需要对此主题进行前瞻性多中心研究,纳入更多患者并进行更密切的监测。